Send to

Choose Destination
Vaccine. 2014 Oct 7;32(44):5875-9. doi: 10.1016/j.vaccine.2014.08.001. Epub 2014 Aug 28.

Post-marketing surveillance of live-attenuated Japanese encephalitis vaccine safety in China.

Author information

National Center for ADR Monitoring, China.
China Office of World Health Organization, China.
Chinese Center for Disease Control and Prevention, China.
National Center for ADR Monitoring, China. Electronic address:


Japanese encephalitis (JE) is the most severe form of viral encephalitis in Asia and no specific treatment is available. Vaccination provides an effective intervention to prevent JE. In this paper, surveillance data for adverse events following immunization (AEFI) related to SA-14-14-2 live-attenuated Japanese encephalitis vaccine (Chengdu Institute of Biological Products) was presented. This information has been routinely generated by the Chinese national surveillance system for the period 2009-2012. There were 6024 AEFI cases (estimated reported rate 96.55 per million doses). Most common symptoms of adverse events were fever, redness, induration and skin rash. There were 70 serious AEFI cases (1.12 per million doses), including 9 cases of meningoencephalitis and 4 cases of death. The post-marketing surveillance data add the evidence that the Chengdu institute live attenutated vaccine has a reasonable safety profile. The relationship between encephalitis and SA-14-14-2 vaccination should be further studied.


Live-attenuated Japanese encephalitis vaccine; Post-marketing surveillance; Safety

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center